Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Dose Escalation Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Participants with Pathologically Confirmed Cancer Refractory to Conventional Therapy
Conditions
Interventions
SNK02
Locations
2
United States
Angeles Clinic and Research Institute
Los Angeles, California, United States
Sarcoma Oncology Center
Santa Monica, California, United States
Start Date
August 23, 2023
Primary Completion Date
April 12, 2024
Completion Date
April 12, 2024
Last Updated
November 20, 2024
NCT05919264
NCT04337580
NCT05735080
NCT04657068
NCT07197671
NCT04585750
Lead Sponsor
NKGen Biotech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions